X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (81) 81
index medicus (53) 53
oncology (52) 52
female (37) 37
male (35) 35
hematology (26) 26
middle aged (23) 23
aged (20) 20
antineoplastic agents - therapeutic use (20) 20
cancer (20) 20
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (20) 20
chronic myeloid leukemia (19) 19
adult (18) 18
imatinib mesylate (17) 17
cell line, tumor (16) 16
imatinib (16) 16
animals (15) 15
expression (15) 15
therapy (15) 15
chronic myelogenous leukemia (14) 14
endocrinology & metabolism (14) 14
dasatinib (13) 13
hemic and lymphatic diseases (13) 13
tyrosine kinase inhibitors (13) 13
bcr-abl (12) 12
benzamides (12) 12
chronic myeloid-leukemia (12) 12
leukemia (12) 12
biochemistry & molecular biology (11) 11
carcinoma (11) 11
mice (11) 11
cml (10) 10
fusion proteins, bcr-abl - genetics (10) 10
protein kinase inhibitors - therapeutic use (10) 10
pyrimidines - therapeutic use (10) 10
risk factors (10) 10
thyroid neoplasms - genetics (10) 10
apoptosis (9) 9
cell biology (9) 9
cell proliferation (9) 9
chemistry (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - pathology (9) 9
mutation (9) 9
phosphorylation (9) 9
thyroid cancer (9) 9
antineoplastic agents - pharmacology (8) 8
fusion proteins, bcr-abl - metabolism (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - genetics (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (8) 8
pyrimidines - pharmacology (8) 8
resistance (8) 8
thyroid neoplasms - metabolism (8) 8
thyroid neoplasms - pathology (8) 8
treatment outcome (8) 8
diagnosis (7) 7
follow-up (7) 7
insulin (7) 7
kinases (7) 7
medicine (7) 7
myeloid leukemia (7) 7
piperazines - pharmacology (7) 7
prognosis (7) 7
protein kinase inhibitors - adverse effects (7) 7
pyrimidines - administration & dosage (7) 7
research (7) 7
risk (7) 7
adolescent (6) 6
aged, 80 and over (6) 6
antineoplastic agents (6) 6
antineoplastic agents - adverse effects (6) 6
hematology, oncology and palliative medicine (6) 6
human necessities (6) 6
hygiene (6) 6
medical or veterinary science (6) 6
metallurgy (6) 6
organic chemistry (6) 6
patients (6) 6
peptides (6) 6
piperazines - therapeutic use (6) 6
preparations for medical, dental, or toilet purposes (6) 6
protein kinase inhibitors - administration & dosage (6) 6
protein-tyrosine kinases - antagonists & inhibitors (6) 6
proteins (6) 6
recommendations (6) 6
research article (6) 6
review (6) 6
thiazoles - therapeutic use (6) 6
tumors (6) 6
tyrosine (6) 6
abridged index medicus (5) 5
analysis (5) 5
antimitotic agents (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
biology (5) 5
chemotherapy (5) 5
cml patients (5) 5
gene expression regulation, neoplastic - drug effects (5) 5
genetic aspects (5) 5
in-vitro (5) 5
incidence (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis
Journal Article
Endocrine-Related Cancer, ISSN 1351-0088, 12/2009, Volume 16, Issue 4, pp. 1103 - 1123
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 01/2015, Volume 27, Issue 1, pp. 1 - 7
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2011, Volume 17, Issue 15, pp. 4942 - 4947
Journal Article
by Bonomi, Marco and Vezzoli, Valeria and Krausz, Csilla and Guizzardi, Fabiana and Vezzani, Silvia and Simoni, Manuela and Bassi, Ivan and Duminuco, Paolo and Di Iorgi, Natascia and Giavoli, Claudia and Pizzocaro, Alessandro and Russo, Gianni and Moro, Mirella and Fatti, Letizia and Ferlin, Alberto and Mazzanti, Laura and Zatelli, Maria Chiara and Cannavò, Salvo and Isidori, Andrea M and Pincelli, Angela Ida and Prodam, Flavia and Mancini, Antonio and Limone, Paolo and Tanda, Maria Laura and Gaudino, Rossella and Salerno, Mariacarolina and Francesca, Pregnolato and Maghnie, Mohamad and Maggi, Mario and Persani, Luca and Aimaretti, G and Altobell, M and Ambrosio, M.R and Andrioli, M and Angelett, G and Arecco, F and Arnald, G and Arosio, M and Balsamo, A and Baldassarr, M and Bartalena, L and Bazzon, N and Beccari, L and Beck-Peccoz, P and Bellastella, G and Bellizz, M and Benedicent, F and Bernasconi, S and Bizzarri, C and Bona, G and Bonadonna, S and Borrett, G and Boschetti, M and Brunani, A and Brunelli, V and Buz, F and Cacciatore, C and Cangiano, B and Cappa, M and Casalone, R and Cassio, A and Cavarzere, P and Cherubini, V and Ciampani, T and Cicognan, D and Cignarell, A and Cisternin, M and Colombo, P and Corbetta, S and Corciul, N and Corona, G and Cozzi, R and Crivellaro, C and Dalle Mule, I and Danesi, L and Eli, A.V.D and Degli Uberti, E and De Leo, S and Della Valle, E and De Marchi, M and Di Iorgi, N and Di Mambr, A and Fabbri, A and Foresta, C and Forti, G and Franceschi, A.R and Garolla, A and Ghezzi, M and Giacomozzi, C and Giusti, M and Grosso, E and Guabello, G and Guarneri, M.P and Grugni, G and Lanfranco, F and Lania, A and Lanzi, R and Larizza, L and Lenzi, A and Loche, S and ... and Italian Network Cent Hypogonadism and Italian Network on Central Hypogonadism (NICe)
European Journal of Endocrinology, ISSN 0804-4643, 01/2018, Volume 178, Issue 1, pp. 23 - 32
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 11/2018, Volume 19, Issue 11, p. 3615
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 01/2017, Volume 5
Journal Article
Endocrine-related cancer, ISSN 1351-0088, 05/2019, Volume 26, Issue 8, pp. 713 - 725
Thyroid cancer incidence is increased in volcanic areas where environment pollution biocontaminates residents. Tungsten (W) is the most increased heavy metal... 
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2012, Volume 130, Issue 10, pp. 2259 - 2270
Most undifferentiated thyroid carcinomas express p53 mutants and thereafter, are very resistant to chemotherapy. p53 reactivation and induction of massive... 
apoptosis | thyroid cancer | p53 mutant | cell proliferation | Prima‐1 | p73 | Prima-1 | CHEMOSENSITIVITY | HISTONE DEACETYLASE INHIBITOR | TUMOR-SUPPRESSOR ACTIVITY | FAMILY | LUNG-CANCER | IN-VITRO | ONCOLOGY | GENE-THERAPY | CARCINOMA | Medical research | Thyroid cancer | Cell cycle | Apoptosis
Journal Article
Future Oncology, ISSN 1479-6694, 11/2015, Volume 11, Issue 24s, pp. 29 - 33
The increasing incidence and the dismal prognosis of malignant pleural mesothelioma calls for the identification of biomarkers that will allow a timely... 
FDG-PET | gene arrays | Ki-67 | malignant pleural mesothelioma | CALGB score | EORTC score | NRL | nuclear grading score | fibulin-3 | mesothelin | SURVIVAL | VALIDATION | MARKERS | MODEL | CANCER | ONCOLOGY | EXTRAPLEURAL PNEUMONECTOMY | INDEX
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2017, Volume 23, Issue 23, pp. 7189 - 7198
Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML) has generated an... 
Tyrosine | BCR protein | Imatinib | Transformation | Myeloid leukemia | Leukemia | Chronic myeloid leukemia | Kinases | Patients | Intolerance | Experimental design | Diagnosis | Protein-tyrosine kinase | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2014, Volume 9, Issue 7, p. e101848
Journal Article